{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:47:38Z","timestamp":1787507258773,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"19","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Idorsia Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/hmg\/ddy248","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T14:51:06Z","timestamp":1530715866000},"page":"3392-3403","source":"Crossref","is-referenced-by-count":45,"title":["Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types"],"prefix":"10.1093","volume":"27","author":[{"given":"R W D","family":"Welford","sequence":"first","affiliation":[{"name":"Idorsia Pharmaceuticals, Hegenheimermattweg, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"M\u00fchlemann","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals, Hegenheimermattweg, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Garzotti","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals, Hegenheimermattweg, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rickert","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M A","family":"Groenen","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals, Hegenheimermattweg, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Morand","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals, Hegenheimermattweg, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Probst","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals, Hegenheimermattweg, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"key":"key\n\t\t\t\t20180917102211_ref1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"key\n\t\t\t\t20180917102211_ref2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal storage diseases\u2013the horizon expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"key\n\t\t\t\t20180917102211_ref3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-444-62702-5.00017-2","article-title":"Fabry disease","volume":"132","author":"Schiffmann","year":"2015","journal-title":"Handb. Clin. Neurol."},{"key":"key\n\t\t\t\t20180917102211_ref4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/gm13","article-title":"The Human Gene Mutation Database: 2008 update","volume":"1","author":"Stenson","year":"2009","journal-title":"Genome Med."},{"key":"key\n\t\t\t\t20180917102211_ref5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","article-title":"Sequelae of storage in Fabry disease\u2013pathology and comparison with other lysosomal storage diseases","volume":"92","author":"Elleder","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"key\n\t\t\t\t20180917102211_ref6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"key\n\t\t\t\t20180917102211_ref7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"key\n\t\t\t\t20180917102211_ref8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"key\n\t\t\t\t20180917102211_ref9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2016.07.001","article-title":"Fabry disease: a disorder of childhood onset","volume":"64","author":"Schiffmann","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"key\n\t\t\t\t20180917102211_ref10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"key\n\t\t\t\t20180917102211_ref11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180917102211_ref12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"Suppl 1","key":"key\n\t\t\t\t20180917102211_ref13","first-page":"S66","article-title":"Anderson-Fabry disease: developments in diagnosis and treatment","volume":"47","author":"Mehta","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"key\n\t\t\t\t20180917102211_ref14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"key\n\t\t\t\t20180917102211_ref15","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"key\n\t\t\t\t20180917102211_ref16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"key\n\t\t\t\t20180917102211_ref17","doi-asserted-by":"crossref","first-page":"e0152812","DOI":"10.1371\/journal.pone.0152812","article-title":"One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180917102211_ref18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"key\n\t\t\t\t20180917102211_ref19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"key\n\t\t\t\t20180917102211_ref20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"key\n\t\t\t\t20180917102211_ref21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10038-006-0369-6","article-title":"Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"key\n\t\t\t\t20180917102211_ref22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"key\n\t\t\t\t20180917102211_ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"key\n\t\t\t\t20180917102211_ref24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated nhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"key\n\t\t\t\t20180917102211_ref25","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180917102211_ref26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"key\n\t\t\t\t20180917102211_ref27","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"key\n\t\t\t\t20180917102211_ref28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"key\n\t\t\t\t20180917102211_ref29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"key\n\t\t\t\t20180917102211_ref30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1358\/dot.2006.42.1.937457","article-title":"Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders","volume":"42","author":"Lachmann","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"key\n\t\t\t\t20180917102211_ref31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/TCRM.S73226","article-title":"Profile of eliglustat tartrate in the management of Gaucher disease","volume":"12","author":"Sechi","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"key\n\t\t\t\t20180917102211_ref32","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180917102211_ref33","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/hmg\/ddx032","article-title":"Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease","volume":"26","author":"Shen","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"key\n\t\t\t\t20180917102211_ref34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0957-4166(99)00468-1","article-title":"Molecular requirement of iminosugars for the selective control of N-linked glycosylation and glycosphingoplipid biosynthesis","volume":"11","author":"Butters","year":"2000","journal-title":"Tetrahedron: Asymmetry"},{"key":"key\n\t\t\t\t20180917102211_ref35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nbd.2004.04.012","article-title":"Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease","volume":"16","author":"Andersson","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"key\n\t\t\t\t20180917102211_ref36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.neuint.2007.12.001","article-title":"N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice","volume":"52","author":"Baek","year":"2008","journal-title":"Neurochem. Int."},{"key":"key\n\t\t\t\t20180917102211_ref37","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.ymgme.2016.11.369","article-title":"Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence","volume":"120","author":"Welford","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"key\n\t\t\t\t20180917102211_ref38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","article-title":"Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Guerard","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"key\n\t\t\t\t20180917102211_ref39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"key\n\t\t\t\t20180917102211_ref40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"key\n\t\t\t\t20180917102211_ref41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/GIM.0b013e318133fb1b","article-title":"The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"9","author":"Clarke","year":"2007","journal-title":"Genet. Med."},{"key":"key\n\t\t\t\t20180917102211_ref42","doi-asserted-by":"crossref","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral migalastat HCl leads to greater systemic exposure and tissue levels of active alpha-galactosidase A in Fabry patients when co-administered with infused agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180917102211_ref43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","article-title":"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice","volume":"46","author":"Kasperzyk","year":"2005","journal-title":"J. Lipid Res."},{"key":"key\n\t\t\t\t20180917102211_ref44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1087057113501197","article-title":"A phenotypic compound screening assay for lysosomal storage diseases","volume":"19","author":"Xu","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"key\n\t\t\t\t20180917102211_ref45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","article-title":"Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease","volume":"37","author":"Itier","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"key\n\t\t\t\t20180917102211_ref46","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1194\/jlr.M100423-JLR200","article-title":"Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases","volume":"43","author":"Asfaw","year":"2002","journal-title":"J. Lipid Res."},{"key":"key\n\t\t\t\t20180917102211_ref47","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1016\/S0021-9258(19)86664-4","article-title":"Studies on human liver alpha-galactosidases. II. Purification and enzymatic properties of alpha-galactosidase B (alpha-N-acetylgalactosaminidase)","volume":"254","author":"Dean","year":"1979","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20180917102211_ref48","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.1074\/jbc.M113.463562","article-title":"beta-Glucosidase 2 (GBA2) activity and imino sugar pharmacology","volume":"288","author":"Ridley","year":"2013","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20180917102211_ref49","doi-asserted-by":"crossref","first-page":"e0135889","DOI":"10.1371\/journal.pone.0135889","article-title":"Reducing GBA2 activity ameliorates neuropathology in Niemann-Pick type C mice","volume":"10","author":"Marques","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180917102211_ref50","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"key\n\t\t\t\t20180917102211_ref51","doi-asserted-by":"crossref","first-page":"e21758","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180917102211_ref52","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fpls.2017.01026","article-title":"Human alpha galactosidases transiently produced in nicotiana benthamiana leaves: new insights in substrate specificities with relevance for Fabry disease","volume":"8","author":"Kytidou","year":"2017","journal-title":"Front Plant Sci."},{"key":"key\n\t\t\t\t20180917102211_ref53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"key\n\t\t\t\t20180917102211_ref54","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1021\/acs.analchem.7b01442","article-title":"Glucosylceramide and glucosylsphingosine quantitation by liquid chromatography-tandem mass spectrometry to enable in vivo preclinical studies of neuronopathic Gaucher disease","volume":"89","author":"Hamler","year":"2017","journal-title":"Anal. Chem."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/27\/19\/3392\/25741191\/ddy248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T19:12:57Z","timestamp":1720379577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/27\/19\/3392\/5049389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":54,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2018,8,8]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddy248","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,8,8]]}}}